INCY Stock — Incyte Corp.

Incyte Corp. (INCY)

Updated October 16, 2026.

INCY is a Stock. Total return is 5930.4% over the past 32.9 years, 3043.8 points ahead of SPY at 2886.6%.

Incyte Corporation is a biopharmaceutical company that discovers, develops, and commercializes therapeutic drugs, with marketed products including JAKAFI for myelofibrosis and related blood disorders, ICLUSIG for certain leukemias, MONJUVI/MINJUVI for lymphomas, and several other oncology and dermatology treatments, along with a pipeline of clinical-stage candidates. The company does not currently have an established distribution schedule. Incyte appeals primarily to growth-oriented equity investors focused on the biopharmaceutical sector, as the company reinvests revenues into research and development rather than paying dividends.

INCY performance versus SPY

Price and return data through 2026-10-16.

Total return is 5930.4% over the past 32.9 years, 3043.8 points ahead of SPY at 2886.6%. Over the past year its total return — price change plus distributions reinvested — is 29.5%. Its deepest 1-year drawdown was 18.3%.

INCY key facts

Asset type

Stock

Asset class

Equity

Inception date

11/04/1993

Distribution frequency

None

Last close

$113.07 (as of 2026-10-16)

Market cap

$22,919,034,140

Average volume

1580116.0

Beta

0.739

Payout ratio

0.0%

P/E ratio

14.01

Forward P/E

14.7059

EPS

$8.07

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

INCY risks and drawbacks

The deepest 1-year drawdown on record here is 18.3%.

Who may consider INCY — and who may not

It is a weaker fit for investors who need monthly cash flow (INCY does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on INCY

• All tickers starting with I

Tagged: Pharmaceutical.

Frequently asked questions